Neurocritical Care News

People with behavioral variant frontotemporal dementia were more likely to exhibit apathy and functional decline, even in the mildest stage of dementia, compared with patients with Alzheimer’s disease, researchers recently reported.

A blood-based biomarker test aided diagnosis and clinical management of Alzheimer’s disease by detecting brain amyloidosis in symptomatic patients, researchers reported at the Clinical Trials for Alzheimer’s Disease annual meeting.

Stressors in life can contribute to poor functional, cognitive and neuropsychiatric outcomes up to a year after being hospitalized with COVID-19, researchers reported in the Journal of Neurological Science.

The use of restorative hearing devices for hearing loss was associated with a 19% decrease in risk for long-term cognitive decline, as well as improvement in cognitive test scores in the short term, researchers reported in JAMA Neurology.

Consuming more than 20% of total daily calories from ultra-processed foods was associated with faster decline in cognition and executive function, researchers reported in JAMA Neurology.

The Alzheimer’s Association is among a group of professional societies and research institutions that have launched the Alzheimer’s Network for Treatment and Diagnostics to collect data on patients treated with novel FDA-approved therapies.

Changes in gene expression patterns in the brain associated with natural aging also were observed in the brains of those with severe COVID-19, prompting researchers to emphasize the need for neurological follow-up in recovered individuals.

Both moderate aerobic exercise and stretching and balance activities protected against cognitive decline in older adults with mild cognitive impairment, according to research at the Clinical Trials on Alzheimer’s Disease annual meeting.

Biogen announced that the European Medicines Agency has accepted the marketing authorization application for tofersen, an investigational drug for the treatment of superoxide dismutase 1 ALS.

Medical device company WISE Srl announced the FDA granted clearance for its Cortical Strip, a single-use device intended to be used on the brain surface for intraoperative neurophysiological monitoring.